The nation of Zimbabwe has rejected a major American healthcare agreement worth $367m (272 million pounds) spanning five years due to the United States' insistence on sensitive data.
The decision came to light after a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative later stated that the United States was demanding access to genetic material for research and profit but was unwilling to share the benefits from future medical innovations.
"We will now turn to the difficult and regrettable task of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for continued dialogue to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can continue.
Broader Background
This rejection comes after a similar case in neighbouring Kenya, where a high court suspended a related deal with the US after legal challenges were filed about the safety of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking government-to-government deals to boost transparency and accountability.
Based on statements, Sixteen African countries have so far agreed to similar health pacts, constituting over $18.3bn in committed funds.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," his statement read.
"In essence, our country would supply the basic resources for medical research without any assurance that the resulting innovations would be accessible to our population if a future pandemic arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of bilateral health agreements were disrupting systems previously set up through the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This system is designed to guarantee that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage ongoing dialogue with our US partners on how future collaboration might be structured in a way that honours the sovereignty and interests of each country."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but urged that talks need to persist since much of the country's Aids initiatives relied on external financing.
"In cases where technical issues arise, including those relating to information security or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group commented.
This impasse underscores the continuing debate between accepting vital foreign assistance and protecting a country's data in an increasingly data-driven world.